HC Wainwright & Co. Maintains Neutral on Virios Therapeutics, Adjusts Price Target To $5 (25-1 Reverse Stock Split)
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Neutral rating on Virios Therapeutics and adjusted the price target to $5 following a 25-1 reverse stock split.
October 09, 2024 | 6:24 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained a Neutral rating on Virios Therapeutics and adjusted the price target to $5 following a 25-1 reverse stock split.
The Neutral rating suggests no strong buy or sell recommendation, indicating a stable outlook. The price target adjustment to $5 reflects the reverse stock split, which consolidates shares and can affect perceived value. The impact on stock price is neutral as the rating remains unchanged.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100